Feng Yang

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.

M. Krempf, P. Hopkins, E. Bruckert, 2019, Journal of clinical lipidology.

Impact of COVID-19 Pandemic on Elevated Anxiety Symptoms of Maintenance Hemodialysis Patients in China: A One-Year Follow-Up Study

Hongbao Liu, H. Lv, Mengqiu Wang, 2022, Frontiers in Psychiatry.

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

John D. Davis, N. Al-Huniti, M. Sale, 2021, CPT: pharmacometrics & systems pharmacology.

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

A. Hawes, G. Yancopoulos, Elzbieta Wloga, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

John D. Davis, N. Al-Huniti, J. Bosley, 2021, CPT: pharmacometrics & systems pharmacology.

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

John D. Davis, I. Lowy, K. Papadopoulos, 2021, Advances in Therapy.

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies

John D. Davis, A. Paccaly, A. T. Dicioccio, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

G. Yancopoulos, J. Gromada, J. Harp, 2017, Diabetes, obesity & metabolism.